Sanofi(US:SNY) 2 1 Shi Ji Jing Ji Bao Dao·2025-09-08 00:42Group 1: Pharmaceutical Companies and Products - 63 pharmaceutical companies have been exposed for serious credit violations, with 63 companies rated as "particularly serious" or "serious" by the National Medical Insurance Administration [1] - Junshi Biosciences announced positive results from a Phase III clinical trial of JS005 for moderate to severe plaque psoriasis, planning to submit a marketing application soon [1] - Sanofi's teplizumab injection has been approved in China for delaying the progression of type 1 diabetes in patients aged 8 and above [2] Group 2: Corporate Actions - Yingke Medical adjusted its share repurchase price limit from RMB 26.51 to RMB 41.88 per share, effective from September 8, 2025, with a total repurchase fund of RMB 80 million to 120 million [3] - Qidi Pharmaceutical plans to change its name to "Guhan Health Industry Group Co., Ltd." and will revise its articles of association accordingly [4] - Jiuan Medical intends to cancel 9.77 million shares, which is 2.06% of its total share capital, as part of a strategy to enhance shareholder returns [5] Group 3: Market Movements and Regulations - Xiangrikui is planning to acquire controlling stakes in Xi Pu Materials and 40% of Beid Pharmaceutical, leading to a temporary suspension of its stock [6] - Beijing has launched a free HPV vaccination program for new first-year junior high school girls, aiming to increase vaccination rates [7][8] - Two studies on iza-bren (EGFR×HER3 dual antibody ADC) have been selected for the official news release program at the 2025 WCLC, highlighting its clinical significance [9] Group 4: Shareholder Actions - Chengda Pharmaceutical announced that a shareholder plans to reduce their stake by up to 7.27% within three months [10] - Kangchen Pharmaceutical's controlling shareholder plans to reduce their stake by up to 3% between September 29 and December 28, 2025, due to personal funding needs [11]